400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
2025-01-09
眼部和中枢神经系统疾病基因疗法研发商
医药研发/制造
化学&生物药
诺和诺德;
诺和诺德;
Bpifrance;
Bpifrance;
Fund+;
Kurma Partners;
Omnes Capital;
Turenne Capital;
Invus;
UI Investissement;
Seroba Life Sciences
2023-12-12
生物制药商
医药研发/制造
化学&生物药
AMR Action Fund;
AMR Action Fund;
EIC Fund;
EIC Fund;
BNP Paribas Development;
IRDI Capital Investissement;
Relyens Innovation Santé;
Turenne Capital
2023-03-14
药物开发商
医药研发/制造
化学&生物药
Omnes Capital;
Omnes Capital;
UI Investissement;
UI Investissement;
Relyens Innovation Santé;
Turenne Capital
2023-01-06
创新治疗肽开发商
医药研发/制造
化学&生物药
2022-05-10
小分子药物开发商
医药研发/制造
化学&生物药
Omnes Capital;
Omnes Capital;
Theodorus Investment Funds;
Theodorus Investment Funds;
CTI Life Sciences Fund;
adMare;
Seventure Partners;
瑞伏医疗创投基金;
Turenne Capital;
Schroders Capital;
3B Future Health Fund
2021-11-09
基因组学技术及产品研发商
医药研发/制造
化学&生物药
SHS Capital;
SHS Capital;
Turenne Capital;
Turenne Capital;
Kurma Partners;
Verve Ventures;
Eurazeo;
Aurinvest
2021-09-16
创新治疗肽开发商
医药研发/制造
化学&生物药
Sectoral Asset Management;
Sectoral Asset Management;
Turenne Capital;
Turenne Capital;
Sham Innovation Santé;
Eurazeo;
Pontifax;
奥博资本;
Bpifrance;
InnoBio 2;
Mass General Brigham Ventures;
Kurma Partners;
诺和诺德;
Life Sciences Partners;
ATEM Capital;
Andera Partners
GlobeNewswire2026-03-10
PRNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
GlobeNewswire2026-03-10
PRNewswire2026-03-10
PRNewswire2026-03-10